Teva UK Ltd v Gilead Sciences Inc.

Core Citations

CONSIDERS

• L-B (Children)
• Nikken Kosakusho Works v Pioneer Trading Company
• Teva UK Ltd Accord Healthcare Ltd Lupin Ltd and Lupin Europe Ltd Generics (UK) Ltd Trading as Mylan v Gilead Sciences Inc.

[See more]

• Eli Lilly and Company Ltd v Human Genome Sciences Inc. (No 2)

REFERS TO

• Warner-Lambert Company LLC v Generics (UK) Ltd (trading as Mylan) and Others
• Eli Lilly and Company v Human Genome Sciences Inc.

CITES

• Nikken Kosakusho Works v Pioneer Trading Company
• Nokia GmbH v IPCOM Gmbh
• Warner-Lambert Company LLC v Generics (UK) Ltd (trading as Mylan) and Others

[See more]

• Vector Corporation v Glatt Air Techniques Inc.

CONSIDERED in

• Regen Lab SA v Estar Medical Ltd
• Gilead Sciences Inc.

APPLIED in

• Eli Lilly and Company v Genentech, Inc.
• Merck Sharp & Dohme Ltd v Clonmel Healthcare Ltd

REFERRED in

• Gilead Sciences, Inc. v Mylan S.A.S., Generics (U.K.) Ltd T/A Mylan

CITED in

• Regen Lab SA v Estar Medical Ltd

This document cites

• Vector Corporation v Glatt Air Techniques Inc.
• Eli Lilly and Company v Human Genome Sciences Inc.
• Teva UK Ltd Accord Healthcare Ltd Lupin Ltd and Lupin Europe Ltd Generics (UK) Ltd Trading as Mylan v Gilead Sciences Inc.
• L-B (Children)
• Nikken Kosakusho Works v Pioneer Trading Company



See all quotations

• Nokia GmbH v IPCOM Gmbh
• Eli Lilly and Company Ltd v Human Genome Sciences Inc. (No 2)
• Nikken Kosakusho Works v Pioneer Trading Company
• Re L and another (Children) (Preliminary Finding: Power to Reverse)
• Teva UK Ltd and Others v Gilead Sciences Inc.
• Warner-Lambert Company LLC v Generics (UK) Ltd (trading as Mylan) and Others
• Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version) (Text with EEA relevance)